1A4Y
RIBONUCLEASE INHIBITOR-ANGIOGENIN COMPLEX
External Resource: Annotation
- Domain Annotation: SCOP/SCOPe Classification
- Domain Annotation: SCOP2 Classification
- Domain Annotation: ECOD Classification
- Domain Annotation: CATH
- Protein Family Annotation
- Gene Ontology: Gene Product Annotation
- InterPro: Protein Family Classification
- Pharos: Disease Associations
- Structure Motif: Primary M-CSA Annotation
Domain Annotation: SCOP/SCOPe Classification SCOP-e Database Homepage
Chains | Domain Info | Class | Fold | Superfamily | Family | Domain | Species | Provenance Source (Version) |
---|---|---|---|---|---|---|---|---|
A | d1a4ya_ | Alpha and beta proteins (a/b) | Leucine-rich repeat, LRR (right-handed beta-alpha superhelix) | RNI-like | 28-residue LRR | Ribonuclease inhibitor | human (Homo sapiens ) [TaxId: 9606 ], | SCOPe (2.08) |
C [auth D] | d1a4yd_ | Alpha and beta proteins (a/b) | Leucine-rich repeat, LRR (right-handed beta-alpha superhelix) | RNI-like | 28-residue LRR | Ribonuclease inhibitor | human (Homo sapiens ) [TaxId: 9606 ], | SCOPe (2.08) |
B | d1a4yb_ | Alpha and beta proteins (a+b) | RNase A-like | RNase A-like | Ribonuclease A-like | Angiogenin | human (Homo sapiens ) [TaxId: 9606 ], | SCOPe (2.08) |
D [auth E] | d1a4ye_ | Alpha and beta proteins (a+b) | RNase A-like | RNase A-like | Ribonuclease A-like | Angiogenin | human (Homo sapiens ) [TaxId: 9606 ], | SCOPe (2.08) |
Domain Annotation: SCOP2 Classification SCOP2 Database Homepage
Chains | Type | Family Name | Domain Identifier | Family Identifier | Provenance Source (Version) |
---|---|---|---|---|---|
A | SCOP2B Superfamily | RNI-like | 8035352 | 3000990 | SCOP2B (2022-06-29) |
C [auth D] | SCOP2B Superfamily | RNI-like | 8035352 | 3000990 | SCOP2B (2022-06-29) |
B | SCOP2B Superfamily | RNase A-like | 8040055 | 3001918 | SCOP2B (2022-06-29) |
D [auth E] | SCOP2B Superfamily | RNase A-like | 8040055 | 3001918 | SCOP2B (2022-06-29) |
Domain Annotation: ECOD Classification ECOD Database Homepage
Chains | Family Name | Domain Identifier | Architecture | Possible Homology | Homology | Topology | Family | Provenance Source (Version) |
---|---|---|---|---|---|---|---|---|
A | LRR_8_4 | e1a4yA1 | A: beta duplicates or obligate multimers | X: Single-stranded right-handed beta-helix | H: Leucine-rich repeats (From Topology) | T: Leucine-rich repeats | F: LRR_8_4 | ECOD (1.6) |
C [auth D] | LRR_8_4 | e1a4yD1 | A: beta duplicates or obligate multimers | X: Single-stranded right-handed beta-helix | H: Leucine-rich repeats (From Topology) | T: Leucine-rich repeats | F: LRR_8_4 | ECOD (1.6) |
B | RnaseA | e1a4yB1 | A: a+b complex topology | X: RNase A-like | H: RNase A-like (From Topology) | T: RNase A-like | F: RnaseA | ECOD (1.6) |
D [auth E] | RnaseA | e1a4yE1 | A: a+b complex topology | X: RNase A-like | H: RNase A-like (From Topology) | T: RNase A-like | F: RnaseA | ECOD (1.6) |
Domain Annotation: CATH CATH Database Homepage
Chain | Domain | Class | Architecture | Topology | Homology | Provenance Source (Version) |
---|---|---|---|---|---|---|
A | 3.80.10.10 | Alpha Beta | Alpha-Beta Horseshoe | Leucine-rich repeat, LRR (right-handed beta-alpha superhelix) | Ribonuclease Inhibitor | CATH (4.3.0) |
C [auth D] | 3.80.10.10 | Alpha Beta | Alpha-Beta Horseshoe | Leucine-rich repeat, LRR (right-handed beta-alpha superhelix) | Ribonuclease Inhibitor | CATH (4.3.0) |
B | 3.10.130.10 | Alpha Beta | Roll | P-30 Protein | Ribonuclease A-like domain | CATH (4.3.0) |
D [auth E] | 3.10.130.10 | Alpha Beta | Roll | P-30 Protein | Ribonuclease A-like domain | CATH (4.3.0) |
Protein Family Annotation Pfam Database Homepage
Chains | Accession | Name | Description | Comments | Source |
---|---|---|---|---|---|
A, C [auth D] | PF13516 | Leucine Rich repeat (LRR_6) | Leucine Rich repeat | - | Repeat |
A, C [auth D] | PF18779 | Capping Ribonuclease inhibitor Leucine Rich Repeat (LRR_RI_capping) | Capping Ribonuclease inhibitor Leucine Rich Repeat | - | Repeat |
B, D [auth E] | PF00074 | Pancreatic ribonuclease (RnaseA) | Pancreatic ribonuclease | Ribonucleases. Members include pancreatic RNAase A and angiogenins. Structure is an alpha+beta fold -- long curved beta sheet and three helices. | Domain |
Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage
InterPro: Protein Family Classification InterPro Database Homepage
Chains | Accession | Name | Type |
---|---|---|---|
A, C [auth D] | IPR001611 | Leucine-rich repeat | Repeat |
A, C [auth D] | IPR032675 | Leucine-rich repeat domain superfamily | Homologous Superfamily |
A, C [auth D] | IPR041302 | Ribonuclease inhibitor, leucine rich repeat cap | Repeat |
A, C [auth D] | IPR050637 | NLRP family, innate immunity and inflammation regulators | Family |
A, C [auth D] | IPR006553 | Leucine-rich repeat, cysteine-containing subtype | Repeat |
B, D [auth E] | IPR036816 | Ribonuclease A-like domain superfamily | Homologous Superfamily |
B, D [auth E] | IPR001427 | Pancreatic ribonuclease | Family |
B, D [auth E] | IPR023411 | Ribonuclease A, active site | Active Site |
B, D [auth E] | IPR023412 | Ribonuclease A-domain | Domain |
Pharos: Disease Associations Pharos Homepage Annotation
Structure Motif Annotation: Mechanism and Catalytic Site Atlas M-CSA Database Homepage
Chains | Enzyme Name | Description | Catalytic Residues |
---|---|---|---|
ribonuclease V M-CSA #564 | Angiogenin is a ribonuclease which induces neovascularisation. It binds specifically to endothelial cells in culture and elicits second-messenger responses. It also binds heparin and can serve as a substratum for endothelial cell adhesion. Its amino acid sequence is 33% identical to that of bovine pancreatic ribonuclease RNase A and it has the same general catalytic properties as RNase A, however, it differs markedly both in magnitude and in specificity with RNase A. Angiogenin was first isolated from culture medium conditioned by adenocarcinoma cells, and has since been shown to be critical for the establishment and/or metastatic spread of a wide variety of human tumours in athymic mice, most likely by supporting the growth of tumour vasculature. Moreover, clinical studies have revealed increased Angiogenin expression to be associated with progression of several human cancers. These findings identify Angiogenin as a promising target for new anticancer drugs. | EC: 3.1.27 (PDB Primary Data) |